Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company
developing T cell-directed vaccines and immunotherapies, today presented
data from a Phase 1 study of GEN-004, an investigational vaccine
designed to prevent disease caused by all serotypes of pneumococcus ( Streptococcus
pneumoniae ) The poster (G-291), titled “Safety and Immunogenicity of
a Novel Lipidated Protein Subunit Streptococcus Pneumoniae vaccine,”
was presented at the 54th Interscience Conference on Antimicrobial
Agents and Chemotherapy (ICAAC) in Washington, DC.
By Jason Meyer
In this week's 'Best of the Trading Deck,' we spotlight columns discussing what's to like about the current setup for speculative growth traders, another with a look at the S&P for the near term, and more.
First-to-Market, Horizontally Mounted—0° to 30° Tilt—String Inverter Solution Increases System Design Flexibility and Project Yield While Enabling Compliance With NEC 2014 Rapid Shutdown Requirements
FORT COLLINS, Colo., Sept.
Sign-up for STAAR 72 HOUR DEADLINE ALERT: Approximately 72 Hours Remain; Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors of Deadline in Securities Class Action Lawsuit Against STAAR Surgical Company - STAA investment picks
Sign-up for VOXX 72 HOUR DEADLINE ALERT: Approximately 72 Hours Remain; Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors of Deadline in Securities Class Action Lawsuit Against VOXX International Corporation - VOXX investment picks
NEW YORK, NY--(Marketwired - September 05, 2014) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Prosensa Holding N.V. ("Prosensa" or the "Company") (NASDAQ: RNA) of the September 16, 2014 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against Prosensa, certain executives and underwriters of the Company's initial public offering ("IPO").
A complaint has been filed in the Southern District of New York on behalf of all persons who purchased or otherwise acquired Prosensa ordinary shares pursuant and/or traceable to the Registration Statement and Prospectus (collectively, the "Registration Statement") issued in connection with
NEW YORK, NY--(Marketwired - September 05, 2014) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Rocket Fuel Inc. ("Rocket Fuel" or the "Company") (NASDAQ: FUEL) of the November 3, 2014 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against Rocket Fuel, certain executives, and the underwriters of the Company's initial public offering.
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.